Investors | LSX Nordic

Apposite Capital

Jeito

Negma group

Monograph Capital 300x

Longliv Ventures 300x

IPF Partners 300x200

Bedrock 300x150

Novozymes

CR Ventures 300x

Caixa Capital-1

Innovestor Ventures

Melior Capital Management 300x150

ACM

BDC

New Rhein-1

Mint Venture

Trill Impact

Aglaia

Novo seeds

Forbion

Noamber foundation

VF Venture

ACM

BVCF

Almi Invest

Apogee Ventures

Novo Nordisk Fonden

Apposite Capital

Astellas

Astrazeneca

Bayer

Canica Holding

CR Ventures

Deutsche Bank

Eight Bridges

Eli Lilly

GEM Global Emerging Markets

Heal Capital

Health Passion Fund

IHM-GBA

Industrifonden

Inventure

Longevity Tech Fund

LSV Capital

Lundbeckfonden

Lynx Capital

Norgine Ventures

Novo Nordisk

Novo Ventures

Octopus Ventures

Organon

Pureos Bioventures

Tesi

Trill Impact

V-Bio Ventures

Lunar Ventures

GIBF

Takeda Digital Ventrures

Hanover 16

Merck

SmiLe Incubator

Health Capital Helsinki 300x

GlobalCoreMedical-1

Taiho Ventures 300x

ABOUT

LSX is the Life Science eXecutive partnering community.

We connect biotech, medtech & healthtech executives with access to the capital, intelligence, innovation, and partners they need to grow their businesses.

EVENTS

Female Founders

Inv€$tival Showcase

European Lifestars Awards

LSX Nordic Congress

LSX USA Congress

LSX World Congress

RNA Leaders Europe

RNA Leaders USA

Workforce Wellbeing

CONNECT

LSX Ltd
Suite 201, Business Design Centre
52 Upper St, London, N1 0QH
United Kingdom